Floatz logo

Serplulimab

Hepatocellular Carcinoma

Explore 499 assets in Hepatocellular Carcinoma →
Floatz Rating
B62/100
Confidence
Indicative
v0.2
Sponsor
Shanghai Henlius Biotech
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06349980CT.gov
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
—Recruiting———
NCT06364046CT.gov
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
—Unknown———
NCT06370065CT.gov
Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
—Unknown———
NCT04465734CT.gov
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
—Withdrawn———
NCT05290220CT.gov
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
—Unknown———
NCT04947826CT.gov
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
—Unknown———
NCT03952403CT.gov
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
—Unknown———
NCT03973112CT.gov
A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hepatocellular Carcinoma

AssetSponsorPhaseRating
Serplulimab (this asset)Shanghai Henlius BiotechP3B · 62
AdefovirBukwang PharmaceuticalP4BBB
Huaier GranuleTongji HospitalP4BBB
FluorouracilumLi QiangP4BBB
OxaliplatinLi QiangP4BBB
TheprubicinRWTH Aachen UniversityP4BB
AdriamycinVA Office of Research and DevelopmentP4BB
nrt6003Second Affiliated Hospital of Guangzhou Medical UniversityP3BB
EpirubicinFudan UniversityP4BB

+42 more in the Hepatocellular Carcinoma cohort

Other indications for Serplulimab

IndicationSponsorPhaseRating
Non-Small Cell Squamous Lung Carcinoma—P3BB · 70
Small Cell Lung Carcinoma—P3BB · 68
Non-Small Cell Lung Carcinoma—P2/3BB · 67

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Serplulimab in Hepatocellular Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/serplulimab-hepatocellular-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →